Investing.com | Editor Rachael Rajan
Published Dec 11, 2024 07:54
On Wednesday, Wells Fargo (NYSE:WFC) adjusted its stance on Editas Medicine (NASDAQ:EDIT), shifting the stock's rating from Overweight to Equal Weight and reducing the price target to $4.00 from the previous $7.00. The change follows the recent presentation of data at the American Society of Hematology (ASH) meeting.
The data presented for Editas Medicine's Reni-cel's hemoglobin (Hb) outcomes appeared consistent with earlier results, featuring a larger sample size and normalized hemolytic markers. However, competing data from another company presented at ASH indicated superior hemoglobin F (HbF) induction and faster engraftment time, which could potentially influence Reni-cel's market position.
Despite this challenge, Wells Fargo noted that Editas Medicine's in vivo sickle cell disease (SCD) program remains a strong candidate to lead in its field and has the potential to significantly increase the company's value. Nonetheless, the program is still in the early stages, and the firm is awaiting further preclinical proof-of-concept results, particularly in lipid nanoparticle (LNP) delivery, as well as clarity on how differences in the payload may perform in vivo.
The revised price target of $4 reflects Wells Fargo's updated assumptions regarding Reni-cel's market penetration. The updated valuation comes as Editas Medicine continues to develop its gene-editing programs, with the industry closely monitoring the progress of such innovative treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.